_220Progress
Explorer
We can bring it back!
All of us are the human trials.
Sharing the data is important.
All of us are the human trials.
Sharing the data is important.
ARA-290 Research Log – Two Subjects with Neuropathy and Chronic Pain
- Thread starter _220Progress
- Start date
_220Progress
Explorer
July 1 update:
Subject A - Increased walk time by 12 seconds without pain.
Subject B - No changes
We were able to to test both subjects vials and we have found the injection site issues root cause.
The PBS was at 10X strength.
This caused the compounds to be painful.
The study: it was a human trial of 4mg-6mg-8mg.
Has the proper reconstitution recipe of PBS:
“(20 mmol/L sodium phosphate buffer, pH 6.5, 1% sucrose and 4% d-mannitol. The results of pharmacokinetic analyses performed in normal volunteers show that following 4 mg SC, a peak plasma level ~3 ng/mL (~2.4 nmol/L) was obtained with a terminal half-life of ~20 min (21). Preclinical pharmacokinetic-pharmacodynamic data has shown that beneficial effects of ARA 290 occur when plasma concentrations exceed 1 nmol/L (2)”
ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes - PMC
Although erythropoietin ameliorates experimental type 2 diabetes with neuropathy, serious side effects limit its potential clinical use. ARA 290, a nonhematopoietic peptide designed from the structure of erythropoietin, interacts selectively with ...
pmc.ncbi.nlm.nih.gov
That confirms that PBS can be used alone to recon ARA-290 at the CORRECT strength.
Next step: Taking 5 new vials of ARA-290 and properly reconstituting for continued use.
Subject A - Increased walk time by 12 seconds without pain.
Subject B - No changes
We were able to to test both subjects vials and we have found the injection site issues root cause.
The PBS was at 10X strength.
This caused the compounds to be painful.
The study: it was a human trial of 4mg-6mg-8mg.
Has the proper reconstitution recipe of PBS:
“(20 mmol/L sodium phosphate buffer, pH 6.5, 1% sucrose and 4% d-mannitol. The results of pharmacokinetic analyses performed in normal volunteers show that following 4 mg SC, a peak plasma level ~3 ng/mL (~2.4 nmol/L) was obtained with a terminal half-life of ~20 min (21). Preclinical pharmacokinetic-pharmacodynamic data has shown that beneficial effects of ARA 290 occur when plasma concentrations exceed 1 nmol/L (2)”
ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes - PMC
Although erythropoietin ameliorates experimental type 2 diabetes with neuropathy, serious side effects limit its potential clinical use. ARA 290, a nonhematopoietic peptide designed from the structure of erythropoietin, interacts selectively with ...
pmc.ncbi.nlm.nih.gov
That confirms that PBS can be used alone to recon ARA-290 at the CORRECT strength.
Next step: Taking 5 new vials of ARA-290 and properly reconstituting for continued use.
Attachments
Can you explain a little more please? Are you saying that the PBS did not create the pain in Subject B and that you are going to use PBS only to reconstitute the vials of ARA-290? Or are you simply saying it is safe to do so and that the PH stays in line if you do?_220Progress said:
July 1 update:
Subject A - Increased walk time by 12 seconds without pain.
Subject B - No changes
We were able to to test both subjects vials and we have found the injection site issues root cause.
The PBS was at 10X strength.
This caused the compounds to be painful.
The study: it was a human trial of 4mg-6mg-8mg.
Has the proper reconstitution recipe of PBS:
“(20 mmol/L sodium phosphate buffer, pH 6.5, 1% sucrose and 4% d-mannitol. The results of pharmacokinetic analyses performed in normal volunteers show that following 4 mg SC, a peak plasma level ~3 ng/mL (~2.4 nmol/L) was obtained with a terminal half-life of ~20 min (21). Preclinical pharmacokinetic-pharmacodynamic data has shown that beneficial effects of ARA 290 occur when plasma concentrations exceed 1 nmol/L (2)”
ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes - PMC
Although erythropoietin ameliorates experimental type 2 diabetes with neuropathy, serious side effects limit its potential clinical use. ARA 290, a nonhematopoietic peptide designed from the structure of erythropoietin, interacts selectively with ...
pmc.ncbi.nlm.nih.gov
That confirms that PBS can be used alone to recon ARA-290 at the CORRECT strength.
Next step: Taking 5 new vials of ARA-290 and properly reconstituting for continued use.
Click to expand...
Attachments
_220Progress
Explorer
Correct.
Subject B’s pain was from the error of 10X PBS.
PBS at proper strength would not cause the pain.
PH is critical.
We will be using PBS at regular strength to recon these next five vials.
Thanks for the question!
Clarity is important!
DazDillinger
Explorer
I tried 4 mg for like 40 days I have sciatica and peripheral neuropathy unfortunately it did nothing
_220Progress
Explorer
Thank you for sharing. Mind sharing how you reconned?
_220Progress
Explorer
Next update will be July 6—————-
July 3 update:
Subject A walking progress [time and distance achieved before pain in back]:
Day 1: 4:02 0.15 mi
Day 3: 6:02 0.22 mi
Day 4: 6:14 0.24 mi
Day 6: 6:50 0.29 mi
Reports General feeling of more mobility before pain.
Subject B:
No change in nerve pain left leg.
Shared that neurologist supports surgery as root cause and has imaging scheduled for identification.
However,
Sleep restlessness from pain has reduced almost 50% Reported per Garmin.
Both subjects are receiving 5 more 10mg vials and will be reconstituted with 2ml PBS at proper strength. Ph to be tested before injections.
Both subjects will be at 4mg daily.
July 3 update:
Subject A walking progress [time and distance achieved before pain in back]:
Day 1: 4:02 0.15 mi
Day 3: 6:02 0.22 mi
Day 4: 6:14 0.24 mi
Day 6: 6:50 0.29 mi
Reports General feeling of more mobility before pain.
Subject B:
No change in nerve pain left leg.
Shared that neurologist supports surgery as root cause and has imaging scheduled for identification.
However,
Sleep restlessness from pain has reduced almost 50% Reported per Garmin.
Both subjects are receiving 5 more 10mg vials and will be reconstituted with 2ml PBS at proper strength. Ph to be tested before injections.
Both subjects will be at 4mg daily.
jmikes
Explorer
I have reconstituted ARA-290 with Hospira BAC water without issue. I didn't know there might be a problem. No ISR in my case.
DazDillinger
Explorer
I used hospira bac. It clumped initially but after it sat overnight all the vials were clear by the morning.
DunningKruger
Explorer
Curious. Does Subject B experience ISRs to only the ARA? Or to the KLOW as well? Is there also a history of allergy/autoimmunity in Subject B?
_220Progress
Explorer
Subject B was only ARA.
They are fine with all other injections.
No history of autoimmune, ANA negative.
My next update sheds some light!
Thanks for the question!
_220Progress
Explorer
July 6 Update:
Subject A: Last few days has been able to achieve further along walks without pain. Notes on exact increase not provided.
Subject B: Newly reconstituted vial with 1ml Bacwater is not causing site issues.
Sleep history review shows a 35% decrease in pain/restlessness wakeups through the night.
Stated during day still same level of nerve pain.
*Subject B was using incorrect recon and is now at proper Ph (confirmed 7.1) injection is 40units:4mg
Subject A: Last few days has been able to achieve further along walks without pain. Notes on exact increase not provided.
Subject B: Newly reconstituted vial with 1ml Bacwater is not causing site issues.
Sleep history review shows a 35% decrease in pain/restlessness wakeups through the night.
Stated during day still same level of nerve pain.
*Subject B was using incorrect recon and is now at proper Ph (confirmed 7.1) injection is 40units:4mg
_220Progress
Explorer
July 10 Update:
Two weeks (14 days) of treatments for both subjects.
If you remove the incorrect recon vials days, it is 9 days of clean treatment.
Subject A is on holiday and doing more walking.
Feedback is that everyday a few more min of pain free walking.
Subject B has seen more improvement on sleeping calmness from pain.
Less interruptions from shock feeling of pain.
During the day, states no change on pain level.
Two weeks (14 days) of treatments for both subjects.
If you remove the incorrect recon vials days, it is 9 days of clean treatment.
Subject A is on holiday and doing more walking.
Feedback is that everyday a few more min of pain free walking.
Subject B has seen more improvement on sleeping calmness from pain.
Less interruptions from shock feeling of pain.
During the day, states no change on pain level.
_220Progress
Explorer
Week of July 11-18
Both subjects are in daily 4mg SubQ injections of ARA-290.
Additional peptides are: KLOW 4mg daily and 1mg BPC-157. Subject A BPC-156 sight location lower back Subject B BPC-157 location is above knee thigh area of nerve impinged leg.
Subject A has seen increased time until pain during walks. Last logged time was 6:22 until pain began.
Subject has asked to continue treatments beyond 28 days if possible.
Subject B has not stated any improvement on nerve pain of left leg during the day. However, nightly sleep tracking has shown a 60% decrease in awaking events and restlessness. Subject states sleep has improved significantly.
They also wish to continue treatments beyond 28 days if possible.
Both subjects are in daily 4mg SubQ injections of ARA-290.
Additional peptides are: KLOW 4mg daily and 1mg BPC-157. Subject A BPC-156 sight location lower back Subject B BPC-157 location is above knee thigh area of nerve impinged leg.
Subject A has seen increased time until pain during walks. Last logged time was 6:22 until pain began.
Subject has asked to continue treatments beyond 28 days if possible.
Subject B has not stated any improvement on nerve pain of left leg during the day. However, nightly sleep tracking has shown a 60% decrease in awaking events and restlessness. Subject states sleep has improved significantly.
They also wish to continue treatments beyond 28 days if possible.
amosmylove
Explorer
Following, this is great info.